Showing 201 - 220 results of 3,581 for search '"bevacizumab"', query time: 0.14s Refine Results
  1. 201
  2. 202
  3. 203
  4. 204
  5. 205

    Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database by Yuko Kanbayashi, Mayako Uchida, Misui Kashiwagi, Hitomi Akiba, Tadashi Shimizu

    Published 2022-09-01
    “…We analysed 5,273,115 reports and identified 20,399 reports of AEs caused by bevacizumab. Of these, 1679 lung toxicities were reportedly associated with bevacizumab. …”
    Get full text
    Article
  6. 206
  7. 207
  8. 208

    PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT by G. S. Emelianova, N. F. Orel, V. A. Gorbunova, A. A. Kolomeytseva, A. A. Kuznetsova, A. E. Kuzminov, A. A. Fedenko

    Published 2017-12-01
    “…Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is actively studied in well differentiated NET. …”
    Get full text
    Article
  9. 209
  10. 210
  11. 211

    Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma by Cedric Brackenier, Lisa Kinget, Sarah Cappuyns, Chris Verslype, Benoit Beuselinck, Jeroen Dekervel

    Published 2023-01-01
    “…The IMbrave150 was a breakthrough study that resulted in atezolizumab/bevacizumab, a combination of an antiangiogenic and an immune checkpoint inhibitor, as a new standard of care for advanced HCC. …”
    Get full text
    Article
  12. 212

    Targeted therapies in the management of renal cell carcinoma: role of bevacizumab by Bernard Escudier, Jan Cosaert, Sangeeta Jethwa

    Published 2008-09-01
    “…Bevacizumab has good tolerability with manageable side effects, both alone and in combination with other agents; the tolerability profile of bevacizumab in combination with IFN is consistent with the well-characterized and well-established profiles of these therapies. …”
    Get full text
    Article
  13. 213
  14. 214
  15. 215
  16. 216
  17. 217
  18. 218
  19. 219

    Intra-ocular pressure changes after intravitreal injection of bevacizumab by Usama Iqbal, Irfan Qayyum Malik, Aamna Jabran

    Published 2022-12-01
    “… Objectives: To evaluate the short-term and sustained intraocular pressure changes after intravitreal bevacizumab in patients with diabetic retinopathy. …”
    Get full text
    Article
  20. 220